Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Long-term Use of Autologous Serum 50% Eye Drops for the Treatment of Dry Eye Disease

Hussain, Munira MS, CCRP; Shtein, Roni M. MD, MS; Sugar, Alan MD; Soong, H. Kaz MD; Woodward, Maria A. MD; DeLoss, Karen OD; Mian, Shahzad I. MD

doi: 10.1097/ICO.0000000000000271
Clinical Science

Purpose: The aim of this study was to describe the outcomes of 50% autologous serum (AS) eye drops after long-term use in a large cohort of patients with dry eyes.

Methods: A retrospective cohort study was conducted on all patients treated with 50% AS eye drops at our institution between June 2008 and January 2013. Records were reviewed for clinical history, systemic risk factors, dry eye etiology, patients' symptoms, and adverse events. Ocular surface evaluation included Schirmer testing with topical anesthesia, fluorescein staining, and ocular surface disease index. Data were reviewed at initial visit, 1 month, and every 3 to 6 months during treatment with AS. Paired t tests were performed to compare the progression of signs and symptoms of dry eye disease.

Results: A total of 123 eyes of 63 patients were evaluated with a mean follow-up of 12 months (range, 3–48 months). Corneal fluorescein staining (mean baseline, 1.77 ± 1.1) improved at the 3- to <6-month, 6- to <12-month, and final follow-up (mean: 1.2 ± 1.0, 1.3 ± 1.0, and 1.1 ± 1.1; P = 0.003, 0.017, and 0.0003, respectively). Schirmer scores (mean baseline, 6.6 ± 6.5 mm) improved at the 12- to 24-month follow-up (mean = 10.7 ± 11.4, P = 0.03), whereas ocular surface disease index scores (mean baseline, 54.1 ± 22.3) improved at the 3- to <6- and 6- to <12-month follow-up (mean: 49.5 ± 8.2 and 39.3 ± 21.4, P = 0.029 and 0.003, respectively). No complications were noted.

Conclusions: Fifty percent AS eye drops seem to be a safe and effective long-term treatment for dry eye disease, especially in patients with severe disease who have exhausted all other conventional forms of treatment.

Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan Medical School, Ann Arbor, MI.

Reprints: Shahzad I. Mian, MD, Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall St, Ann Arbor, MI 48105 (e-mail:

The authors have no funding or conflicts of interest to disclose.

Received February 24, 2014

Received in revised form August 07, 2014

Accepted August 13, 2014

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.